Friday, December 03, 2021

Drug cocktail that could be a saviour: New Covid treatment is FOUR TIMES more effective at keeping patients out of intensive care, tests suggest

A new drug cocktail is four times more effective at keeping Covid patients out of intensive care, initial tests have suggested.

While the steroid dexamethasone was the first drug to be licensed for treating the virus, trials indicate that combining it with heart failure medication spironolactone yields better results.

A study, conducted by former vice-chancellor of Newcastle University Sir Christopher Edwards, analysed hospital patients in Delhi.

He found that, in hospitalised patients taking the ‘Spidex’ cocktail, just 5.4 per cent were admitted to intensive care compared to 19.6 per cent of those taking dexamethasone alone.

Now he is calling for wider trials of the Spidex regime as he believes more lives could be saved.

His findings, published in the journal Frontiers in Endocrinology, revealed 40 Covid patients taking Spidex performed better on every clinical, biochemical and radiological measure than 40 patients on a high dose of dexamethasone.

The treatment works by ‘turning off’ the impact the virus has on the body, rather than targeting the virus itself.

Sir Christopher hopes the combination should also work against the mutated Omicron virus.


Researchers shoot holes in study touted for confirming 'masks work' in curbing COVID

I rubbished this study on 3rd. September

An acclaimed study on the effectiveness of masks in reducing symptomatic COVID-19 is facing new scrutiny after a researcher highlighted the minuscule infection differences between "treatment" and control groups randomized across 600 Bangladeshi villages.

Accused of design flaws and overstating its findings when it was released in late August, the study's newly released data show only 20 more symptomatic COVID cases in the villages that didn't receive masks and related education, reminders and "role modeling by community leaders."

In a total study population of 342,126 adults, 1,106 people in the control group tested positive, compared to 1,086 in the treatment group. The latter group represented 52% of the study population.

"I have a hard time going from these numbers to the assured conclusions that 'masks work' that was promulgated by the media or the authors after this preprint [not yet peer reviewed] appeared," University of California Berkeley professor Ben Recht, who studies machine learning, wrote in an essay last week.

He said he was frustrated that the "raw number of seropositive cases" was left out of the preprint by researchers led by Yale University economists Jason Abaluck and Ahmed Mobarak, preventing him from "computing standard statistical analyses of their results."

The researchers posted the replication code and data in early November, long after media coverage touting "the largest randomized trial to demonstrate the effectiveness of surgical masks, in particular, to curb transmission of the coronavirus."

In light of the full release, "a complex intervention including an educational program, free masks, encouraged mask wearing, and surveillance in a poor country with low population immunity and no vaccination showed at best modest reduction in infection," Recht said.

The newly provided raw numbers exacerbate other weaknesses of the study, according to Recht, who was also initially skeptical of the research because of its "statistical ambiguity."

The study was not blinded, did not exclude pre-intervention infections, and was "highly complex" because of the mixed interventions, he said.

The three-percentage-point differential between household visit consent rates for the treatment and control groups, by itself, "could wash away the difference in observed cases," he explained, adding that relative measures of risk are "[o]ne of the dark tricks of biostatistics," which unlike hard case counts have a tendency to exaggerate effects.

'How robust can this possibly be?'

The UC Berkeley professor's analysis drew attention on Twitter, including from Harvard Medical School epidemiologist Martin Kulldorff, whose own skepticism of the protective power of masks for unvaccinated elderly people got him suspended by Twitter for a month.

"One of the problems of the study is that despite the vast size of the study, the primary endpoint depends on ~5000 blood samples collected" each from the treatment and control groups, Philadelphia cardiologist Anish Koka wrote in a related thread.

"So we are left to extrapolate from a 20 case difference tested in ~10,000 patients to a 300,000 patient study," he continued. "But how robust can this possibly be?"

Koka noted that Yale's Abaluck, a lead author, floated the idea of fining people for not wearing government-supplied cloth masks, the least effective kind, early in the pandemic. "It seems a bit much to go from these small differences to the police tracking down and fining people who don't mask in public," the cardiologist wrote.


Vaccines can kill

At what risk do you take a vaccine that might do more harm than good? Newly released documents support decisions by those who have been reluctant to get a COVID shot. Attorney Aaron Siri has published an initial report addressing information he demanded from the Federal Drug Administration (FDA).

In a discussion with a U.S. Congressional panel led by Senator Ron Johnson, Siri said his law firm had received hundreds of legal requests about COVID vaccination problems. The documents reveal over 150,000 incidents involving side effects have been reported to Pfizer.

Of the thousands of documented side effects, the data indicate more than 25,000 of these have directly affected the central nervous system. These numbers become even more disturbing when we consider the period for claims fell within a short two-and-a-half month window.

This timeframe was during the initial months when Pfizer was distributing vaccines under Emergency Use Authorization (EUA). Pfizer even admits that the company was overwhelmed by, “the large numbers of spontaneous adverse event reports received for the product.”

The alarming ramifications of this data are further supported by shocking revelations within the Vaccine Adverse Effects Reporting System (VAERS) for COVID. There have been over 18,000 deaths resulting from the COVID vaccination and nearly 100,000 hospitalizations.

Nearly 100,000 more adverse vaccination incidents have required urgent care. There are thousands of reported cases of Anaphylaxis and Bell’s palsy. No one expected that there wouldn’t be problems with a hastily approved vaccination.

There aren’t many people fighting against the mandates who dispute that the vaccines have at some level been useful. They take issue with the tyrannical mandating of the COVID vaccine. Joe Biden has overstepped his authority. He is not a dictator, although he thinks he is.

The choice to receive a COVID vaccination should be a personal one. It should involve a thorough consideration of individual health circumstances. “The jab” may not be for everyone. The increasingly disturbing number of reported side effects must be part of the conversation. However, the mainstream media refuses to engage in open discussion.


Get ready for boosters every year: Pfizer boss says annual jabs needed to maintain 'very high protection'

Britons might need a Covid booster every year to maintain 'very high' levels of protection against the, Pfizer's boss said today after the UK ordered 114million more shots from his company and Moderna to vaccinate everyone until 2023.

Dr Albert Bourla, chief executive at the company which delivered the world's first Covid vaccine a year ago today, said global economies will probably need to rely on jabs for years to come to stay on top of new variants and counter waning immunity.

The UK has ordered another 114million doses that can be tweaked to fight off variants — including 54million Pfizer jabs and 60million Moderna doses in a deal thought to be worth around £2.05billion

Officials did not reveal how much the Pfizer jabs cost, but EU contracts show the bloc is spending about £16.50 per dose of Pfizer and £19.50 on Moderna's. They will arrive in 2022 and 2023, with plans already being drawn up to boost the nation's immunity for at least the next two years.




1 comment:

Bob Smith said...

New covid cocktail? Amazing how they try everything but Ivermectin and Hydroxycloroquine.